1. Protein Tyrosine Kinase/RTK Apoptosis
  2. VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis
  3. Cabozantinib

Cabozantinib  (Synonyms: XL184; BMS-907351)

Cat. No.: HY-13016 Purity: 99.96%
SDS COA Handling Instructions

Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.

For research use only. We do not sell to patients.

Cabozantinib Chemical Structure

Cabozantinib Chemical Structure

CAS No. : 849217-68-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
5 mg USD 50 In-stock
10 mg USD 70 In-stock
50 mg USD 90 In-stock
100 mg USD 120 In-stock
200 mg USD 190 In-stock
500 mg USD 380 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 45 publication(s) in Google Scholar

Other Forms of Cabozantinib:

Top Publications Citing Use of Products

41 Publications Citing Use of MCE Cabozantinib

WB

    Cabozantinib purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2017 Nov;16(11):2387-2398.  [Abstract]

    Representative Western blots and densitometry show that cabozantinib reduces phosphorylation of Erk1/2 after 6 hours and reduces cyclin D1 and increases p27 protein levels after 24 hours of treatment (n=3-4).

    Cabozantinib purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Sep 25;12(9):e0185321.  [Abstract]

    Treatment with Cabozantinib results in complete inhibition of the c-MET phosphorylation stimulated by HGF at nanomolar concentrations.

    Cabozantinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Jan 14;59(1):358-73.  [Abstract]

    Autophosphorylation of RET and its downstream signaling are blocked by 6i. The effect of 6i on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3 and (D) RET-V804M Ba/F3. (A-D) Ba/F3 cells, stably transformed with the indicated constructs, are treated for 1 h with gradually increasing concentrations of 7a, Cabozantinib and 6i (0-10 μM) and then lysed. Protein extracts are immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of R

    Cabozantinib purchased from MedChemExpress. Usage Cited in: J Med Chem. 2016 Jan 14;59(1):358-73.  [Abstract]

    Autophosphorylation of RET and its downstream signaling are blocked by 6i. The effect of 6i on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3 and (D) RET-V804M Ba/F3. (A-D) Ba/F3 cells, stably transformed with the indicated constructs, are treated for 1 h with gradually increasing concentrations of 7a, Cabozantinib and 6i (0-10 μM) and then lysed. Protein extracts are immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of R

    View All VEGFR Isoform Specific Products:

    View All TAM Receptor Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].

    IC50 & Target[1]

    VEGFR2

    0.035 nM (IC50)

    Axl

     

    Flt-4

    6 nM (IC50)

    Flt-1

    12 nM (IC50)

    Met

    1.3 ± 1.2 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    A498 IC50
    8456 nM
    Compound: Cabozantinib
    Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A498 cells after 48 hrs by MTT assay
    [PMID: 29057042]
    A549 IC50
    ≥ 50 nM
    Compound: Cabozantinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    A549 IC50
    0.33 μM
    Compound: XL-184
    Antiproliferative activity against human A549 cells expressing c-Met after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing c-Met after 48 hrs by MTT assay
    [PMID: 35227978]
    A549 IC50
    0.76 μM
    Compound: 1; XL-184
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 33601310]
    A549 IC50
    15.23 μM
    Compound: Cabozantinib
    Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    Antiproliferation activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    [PMID: 34186178]
    A549 IC50
    3.75 μM
    Compound: Cabozantinib
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 72 hrs by MTT assay
    [PMID: 31757525]
    A549 IC50
    4205 nM
    Compound: Cabozantinib
    Growth inhibition of human A549 cells incubated for 72 hrs by CCK8 assay
    Growth inhibition of human A549 cells incubated for 72 hrs by CCK8 assay
    [PMID: 28651979]
    A549 IC50
    7.21 μM
    Compound: Cabozantinib
    Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative against human A549 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33045329]
    A549 IC50
    7.8 μM
    Compound: XL-184
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32738414]
    A549 IC50
    8.5 μM
    Compound: Cabozantinib
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
    [PMID: 30940564]
    A549 IC50
    9.52 μM
    Compound: Cabozantinib
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 30503936]
    A549/CDDP IC50
    19.6 μM
    Compound: Cabozantinib
    Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay
    [PMID: 30503936]
    BaF3 GI50
    > 10 μM
    Compound: Cabozantinib
    Cytotoxicity against mouse BA/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay
    Cytotoxicity against mouse BA/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay
    [PMID: 27814560]
    BaF3 GI50
    0.01 μM
    Compound: Cabozantinib
    Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26652860]
    BaF3 IC50
    0.0219 μM
    Compound: Cabozantinib
    Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay
    [PMID: 27068889]
    BaF3 IC50
    0.024 μM
    Compound: Cabozantinib
    Antiproliferative activity against mouse BAF3 cells harboring TRP-MET after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BAF3 cells harboring TRP-MET after 72 hrs by CCK-8 assay
    [PMID: 29146452]
    BaF3 GI50
    0.05 μM
    Compound: Cabozantinib
    Inhibition of wild type TEL-fused RET (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Inhibition of wild type TEL-fused RET (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26652860]
    BaF3 GI50
    0.15 μM
    Compound: Cabozantinib
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay
    [PMID: 29133048]
    BaF3 IC50
    0.18 μM
    Compound: 2
    Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
    Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay
    [PMID: 32292556]
    BaF3 GI50
    0.89 μM
    Compound: Cabozantinib
    Inhibition of TEL-fused Ret V804M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Inhibition of TEL-fused Ret V804M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26652860]
    BaF3 GI50
    0.91 μM
    Compound: Cabozantinib
    Inhibition of TEL-fused Ret V804L mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    Inhibition of TEL-fused Ret V804L mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
    [PMID: 26652860]
    BaF3 GI50
    1.45 μM
    Compound: Cabozantinib
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay
    [PMID: 29133048]
    BaF3 GI50
    1.53 μM
    Compound: Cabozantinib
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay
    [PMID: 29133048]
    BaF3 IC50
    14 nM
    Compound: 2
    Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
    Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
    [PMID: 26874741]
    BaF3 IC50
    190 nM
    Compound: 2
    Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
    Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay
    [PMID: 26874741]
    BaF3 GI50
    2.8 μM
    Compound: Cabozantinib
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay
    [PMID: 29133048]
    BaF3 IC50
    7.5 μM
    Compound: XL184; BMS-907351
    Inhibition of FLT3 (unknown origin) phosphorylation transfected in mouse BAF3 cells incubated for 1 to 3 hrs
    Inhibition of FLT3 (unknown origin) phosphorylation transfected in mouse BAF3 cells incubated for 1 to 3 hrs
    [PMID: 26717201]
    BaF3 GI50
    7.914 μM
    Compound: Cabozantinib
    Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay
    Cytotoxicity against mouse BaF3 cells assessed as reduction in cell proliferation measured after 48 hrs by MTS assay
    [PMID: 32882611]
    BaF3 IC50
    889 nM
    Compound: Cabozantinib
    Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay
    Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay
    [PMID: 27131066]
    BaF3 GI50
    9.36 μM
    Compound: Cabozantinib
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay
    [PMID: 29133048]
    CAKI-1 IC50
    1.66 μM
    Compound: Cabozantinib
    Cytotoxicity against human CAKI-1 cells assessed as reduction cell viability by MTT assay
    Cytotoxicity against human CAKI-1 cells assessed as reduction cell viability by MTT assay
    [PMID: 34175535]
    EBC-1 IC50
    4.8 nM
    Compound: Cabozantinib
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    EBC-1 IC50
    51.4 nM
    Compound: Cabozantinib
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay
    [PMID: 28412159]
    FHC IC50
    4.4 μM
    Compound: Cabozantinib
    Cytotoxicity against human FHC cells after 72 hrs by MTT assay
    Cytotoxicity against human FHC cells after 72 hrs by MTT assay
    [PMID: 30503936]
    HCT-116 IC50
    3.78 μM
    Compound: Cabozantinib
    Cytotoxicity against human HCT-116 cells assessed as reduction cell viability by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction cell viability by MTT assay
    [PMID: 34175535]
    HCT-116 IC50
    4.67 μM
    Compound: XL-184
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32738414]
    HEK293 IC50
    25.8 μM
    Compound: JV-985
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 33214822]
    HeLa IC50
    > 10000 nM
    Compound: XL184
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    [PMID: 31382120]
    HeLa IC50
    > 20 μM
    Compound: Cabozantinib
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31307762]
    HeLa IC50
    0.32 μM
    Compound: 1; XL-184
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 33601310]
    HeLa IC50
    79.06 μM
    Compound: XL-184
    Antiproliferative activity against human HeLa cells expressing c-Met after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells expressing c-Met after 48 hrs by MTT assay
    [PMID: 35227978]
    HepG2 IC50
    12 nM
    Compound: Cabozantinib
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 28412159]
    HepG2 IC50
    15.58 μM
    Compound: Cabozantinib
    Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    [PMID: 34186178]
    HepG2 IC50
    3.05 μM
    Compound: Cabozantinib
    Cytotoxicity against human HepG2 cells assessed as reduction cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction cell viability by MTT assay
    [PMID: 34175535]
    HepG2 IC50
    8.3 μM
    Compound: JV-985
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    [PMID: 33214822]
    HL-60 IC50
    22.46 μM
    Compound: Cabozantinib
    Antiproliferative activity against human HL60 cells harboring wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HL60 cells harboring wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    [PMID: 31466809]
    HT-29 IC50
    10.6 μM
    Compound: Cabozantinib
    Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
    Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
    [PMID: 32731184]
    HT-29 IC50
    11.5 μM
    Compound: Cabozantinib
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 30503936]
    HT-29 IC50
    4.56 μM
    Compound: Cabozantinib
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
    [PMID: 31757525]
    HT-29 IC50
    53 μM
    Compound: Cpd I
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32113049]
    HT-29 IC50
    9.6 μM
    Compound: Cabozantinib
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31307762]
    HT-29 IC50
    9.6 μM
    Compound: Cabozantinib
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
    [PMID: 30940564]
    Huh-7 IC50
    4348 nM
    Compound: Cabozantinib
    Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay
    [PMID: 29057042]
    HUVEC IC50
    45 nM
    Compound: Cabozantinib
    Cytotoxicity against HUVEC after 96 hrs by MTT assay
    Cytotoxicity against HUVEC after 96 hrs by MTT assay
    [PMID: 30248654]
    HUVEC IC50
    7.8 μM
    Compound: XL184; BMS-907351
    Inhibition of VEGFR-2 phosphorylation in HUVEC incubated for 1 to 3 hrs
    Inhibition of VEGFR-2 phosphorylation in HUVEC incubated for 1 to 3 hrs
    [PMID: 26717201]
    HUVEC IC50
    7670 nM
    Compound: XL184
    Antiproliferative activity against HUVEC cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Antiproliferative activity against HUVEC cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    [PMID: 31382120]
    L02 IC50
    54.97 μM
    Compound: 1; XL-184
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 33601310]
    MCF7 IC50
    0.45 μM
    Compound: 1; XL-184
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    [PMID: 33601310]
    MCF7 IC50
    14.26 μM
    Compound: Cabozantinib
    Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    Antiproliferation activity against human MCF-7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    [PMID: 34186178]
    MCF7 IC50
    2889 nM
    Compound: Cabozantinib
    Growth inhibition of human MCF7 cells incubated for 72 hrs by CCK8 assay
    Growth inhibition of human MCF7 cells incubated for 72 hrs by CCK8 assay
    [PMID: 28651979]
    MCF7 IC50
    30.87 μM
    Compound: XL-184
    Antiproliferative activity against human MCF7 cells expressing c-Met after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells expressing c-Met after 48 hrs by MTT assay
    [PMID: 35227978]
    MCF7 IC50
    5.4 μM
    Compound: Cabozantinib
    Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative against human MCF-7 cells assessed as reduction in cell viability by MTT assay
    [PMID: 33045329]
    MCF7 IC50
    5.98 μM
    Compound: XL-184
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 32738414]
    MCF7 IC50
    8.57 μM
    Compound: Cabozantinib
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 30503936]
    MDA-MB-231 IC50
    13.4 μM
    Compound: Cabozantinib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 30503936]
    MDA-MB-231 IC50
    19.72 μM
    Compound: Cabozantinib
    Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    Antiproliferation activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
    [PMID: 34186178]
    MDA-MB-231 IC50
    42 μM
    Compound: XL184; BMS-907351
    Inhibition of KIT (unknown origin) phosphorylation transfected in human MDA-MB-231 cells incubated for 1 to 3 hrs
    Inhibition of KIT (unknown origin) phosphorylation transfected in human MDA-MB-231 cells incubated for 1 to 3 hrs
    [PMID: 26717201]
    MDA-MB-231 IC50
    5 μM
    Compound: XL184; BMS-907351
    Inhibition of AXL phosphorylation in human MDA-MB-231 cells incubated for 1 to 3 hrs
    Inhibition of AXL phosphorylation in human MDA-MB-231 cells incubated for 1 to 3 hrs
    [PMID: 26717201]
    MDA-MB-231 IC50
    5080 nM
    Compound: XL184
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    [PMID: 31382120]
    MKN-45 IC50
    32 μM
    Compound: Cpd I
    Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MKN-45 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32113049]
    MKN-45 IC50
    6.9 nM
    Compound: Cabozantinib
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    MV4-11 IC50
    15.16 μM
    Compound: Cabozantinib
    Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MV4-11 cells harboring FLT3-ITD assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    [PMID: 31466809]
    NCI-H1299 IC50
    1919 nM
    Compound: Cabozantinib
    Growth inhibition of human H1299 cells incubated for 72 hrs by CCK8 assay
    Growth inhibition of human H1299 cells incubated for 72 hrs by CCK8 assay
    [PMID: 28651979]
    NCI-H1975 IC50
    6.67 μM
    Compound: Cabozantinib
    Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31307762]
    NCI-H292 IC50
    ≥ 50 nM
    Compound: Cabozantinib
    Antiproliferative activity against human NCI-H292 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H292 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    NCI-H460 IC50
    3.6 μM
    Compound: Cpd I
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 32113049]
    NCI-H460 IC50
    40.1 nM
    Compound: Cabozantinib
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    NCI-H460 IC50
    5669 nM
    Compound: Cabozantinib
    Growth inhibition of human H460 cells incubated for 72 hrs by CCK8 assay
    Growth inhibition of human H460 cells incubated for 72 hrs by CCK8 assay
    [PMID: 28651979]
    NCI-H727 IC50
    14010 nM
    Compound: Cabozantinib
    Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay
    Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay
    [PMID: 29057042]
    NIH3T3 GI50
    > 10 μM
    Compound: Cabozantinib
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay
    [PMID: 29133048]
    NIH3T3 GI50
    0.1 μM
    Compound: Cabozantinib
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay
    [PMID: 29133048]
    PANC-1 IC50
    5.13 μM
    Compound: Cabozantinib
    Cytotoxicity against human PANC-1 cells assessed as reduction cell viability by MTT assay
    Cytotoxicity against human PANC-1 cells assessed as reduction cell viability by MTT assay
    [PMID: 34175535]
    PC-3 IC50
    1.9 μM
    Compound: XL184; BMS-907351
    Inhibition of c-Met phosphorylation in human PC3 cells incubated for 1 to 3 hrs
    Inhibition of c-Met phosphorylation in human PC3 cells incubated for 1 to 3 hrs
    [PMID: 26717201]
    PC-3 IC50
    3.68 μM
    Compound: Cabozantinib
    Cytotoxicity against human PC-3 cells assessed as reduction cell viability by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction cell viability by MTT assay
    [PMID: 34175535]
    PC-3 IC50
    8.25 μM
    Compound: Cabozantinib
    Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
    [PMID: 31757525]
    Sf21 IC50
    16 nM
    Compound: 2
    Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay
    Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay
    [PMID: 26874741]
    Sf21 IC50
    3 nM
    Compound: Cabozantinib
    Inhibition of wild type N-terminal GST-tagged recombinant human RET (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
    Inhibition of wild type N-terminal GST-tagged recombinant human RET (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
    [PMID: 27131066]
    Sf21 IC50
    811 nM
    Compound: Cabozantinib
    Inhibition of N-terminal GST-tagged recombinant human RET V804M mutant (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
    Inhibition of N-terminal GST-tagged recombinant human RET V804M mutant (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA
    [PMID: 27131066]
    SiHa IC50
    7940 nM
    Compound: XL184
    Antiproliferative activity against human SiHa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human SiHa cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    [PMID: 31382120]
    SNU-5 IC50
    12.1 nM
    Compound: Cabozantinib
    Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay
    [PMID: 30248654]
    SW-620 IC50
    3.37 μM
    Compound: Cabozantinib
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    [PMID: 31307762]
    T47D IC50
    4448 nM
    Compound: Cabozantinib
    Growth inhibition of human T47D cells incubated for 72 hrs by CCK8 assay
    Growth inhibition of human T47D cells incubated for 72 hrs by CCK8 assay
    [PMID: 28651979]
    T47D IC50
    4790 nM
    Compound: XL184
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
    [PMID: 31382120]
    TT GI50
    0.12 μM
    Compound: Cabozantinib
    Inhibition of RET C634W mutant in human TT cells assessed as cell growth inhibition after 10 days by MTT assay
    Inhibition of RET C634W mutant in human TT cells assessed as cell growth inhibition after 10 days by MTT assay
    [PMID: 26652860]
    In Vitro

    Cabozantinib inhibits phosphorylation of MET and VEGFR2, as well as KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 μM, respectively[1].
    Cabozantinib (4.6 nM) inhibits tubule formation with no evidence of cytotoxicity, with IC50 values of 6.7, 5.1, 4.1, 7.7, and 4.7 nM in HMVEC, MDA-MB-231, A431, HT1080, and B16F10 cells, respectively[1].
    Cabozantinib (0-370 nM, 24 h) inhibits cellular migration and invasion[1].
    Cabozantinib (48 h) inhibits tumor cell proliferation in a variety of tumor types[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay

    Cell Line: SNU-5, Hs746T, SNU-1, SNU-16, MDA-MB-231, U87MG, H441, H69, and PC3 cells[1]
    Concentration:
    Incubation Time: 48 hours
    Result: Inhibited tumor cell proliferation, with IC50 of 19, 9.9, 5223, 1149, 6421, 1851, 21700, 20200, and 10800 nM, respectively.

    Cell Migration Assay

    Cell Line: B16F10 cells[1]
    Concentration: 0, 41, 123, and 370 nM
    Incubation Time: 24 hours
    Result: Potently inhibited HGF-induced migration (IC50 = 31 nM) of B16F10 cells.

    Cell Invasion Assay

    Cell Line: B16F10 cells[1]
    Concentration: 0, 1.5, 14, and 123 nM
    Incubation Time: 24 hours
    Result: Potently inhibited HGF-induced invasion (IC50 = 9 nM) of B16F10 cells.
    In Vivo

    Cabozantinib (100 mg/kg, Orally, once) inhibits MET and VEGFR2 phosphorylation in mice[1].
    Cabozantinib (100 mg/kg, Orally, once) significantly increases tumor hypoxia and apoptosis[1].
    Cabozantinib (0-60 mg/kg, Orally, once daily for 14 days) inhibits tumor growth in a dose-dependent manner[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female mice bearing MBA-MB-231 tumor (5 per group)[1]
    Dosage: 0, 100 mg/kg
    Administration: Orally, once
    Result: Inhibited MET and VEGFR2 phosphorylation.
    Animal Model: Mice bearing MBA-MB-231 tumor[1]
    Dosage: 1, 3, 10, 30, 60 mg/kg
    Administration: Orally, once daily for 14 days
    Result: Inhibited tumor growth in a dose-dependent manner.
    Clinical Trial
    Molecular Weight

    501.51

    Formula

    C28H24FN3O5

    CAS No.
    Appearance

    Solid

    Color

    White to gray

    SMILES

    O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 25 mg/mL (49.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9940 mL 9.9699 mL 19.9398 mL
    5 mM 0.3988 mL 1.9940 mL 3.9880 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (4.98 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.15 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  0.5% CMC/saline water

      Solubility: 2.5 mg/mL (4.98 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.96%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9940 mL 9.9699 mL 19.9398 mL 49.8495 mL
    5 mM 0.3988 mL 1.9940 mL 3.9880 mL 9.9699 mL
    10 mM 0.1994 mL 0.9970 mL 1.9940 mL 4.9849 mL
    15 mM 0.1329 mL 0.6647 mL 1.3293 mL 3.3233 mL
    20 mM 0.0997 mL 0.4985 mL 0.9970 mL 2.4925 mL
    25 mM 0.0798 mL 0.3988 mL 0.7976 mL 1.9940 mL
    30 mM 0.0665 mL 0.3323 mL 0.6647 mL 1.6616 mL
    40 mM 0.0498 mL 0.2492 mL 0.4985 mL 1.2462 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cabozantinib
    Cat. No.:
    HY-13016
    Quantity:
    MCE Japan Authorized Agent: